Kobayashi, Daisuke
Kodera, Yasuhiro
Fukushima, Ryoji
Morita, Masaru
Fushida, Sachio
Yamashita, Naoyuki
Yoshikawa, Kozo
Ueda, Shugo
Yabusaki, Hiroshi
Kusumoto, Tetsuya
Arigami, Takaaki
Hidemura, Akio
Omori, Takeshi
Yamaguchi, Hironori
Hirono, Yasuo
Tsuji, Yasushi
Moon, Jeong Ho
Tomita, Toshihiko
Imamura, Hiroshi
Nakanishi, Koki
Shimizu, Dai
Hirakawa, Akihiro
Ishigami, Hironori
Kitayama, Joji
Funding for this research was provided by:
Japan Society of Clinical Oncology (Clinical Trials of Cancer Research Grant Program)
Japan Agency for Medical Research and Development
Article History
Received: 12 April 2023
Accepted: 26 July 2023
First Online: 11 November 2023
Disclosure
: This study was supported in part by funding from Clinical Trials of Cancer Research Grant Program conducted by Japan Society of Clinical Oncology and the Japan Agency for Medical Research and Development. D. Kobayashi received honoraria from Taiho Pharmaceutical Co., Ltd., and Bristol-Myers Squibb Co., Ltd. Y. Kodera received research funding from Taiho Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., and Pfizer Co., Ltd., and honoraria from Taiho Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., and Bristol-Myers Squibb Co., Ltd. S. Ueda received honoraria from Pfizer Co., Ltd. T. Arigami received honoraria from Bristol-Myers Squibb Co., Ltd. A. Hidemura received honoraria from Taiho Pharmaceutical Co., Ltd. T. Omori received research funding from Taiho Pharmaceutical Co., Ltd., and honoraria from Taiho Pharmaceutical Co., Ltd., and Bristol-Myers Squibb Co., Ltd. H. Yamaguchi received research funding from Taiho Pharmaceutical Co., Ltd., and Nippon Kayaku Co., Ltd., and honoraria from Taiho Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., and Bristol-Myers Squibb Co., Ltd. H. Y. Hirono received research funding from Taiho Pharmaceutical Co., Ltd., and honoraria from Taiho Pharmaceutical Co., Ltd. Y. Tsuji received honoraria from Taiho Pharmaceutical Co., Ltd. T. Tomita received honoraria from Taiho Pharmaceutical Co., Ltd., and Bristol-Myers Squibb Co., Ltd. K. Nakanishi received honoraria from Taiho Pharmaceutical Co., Ltd. A. Hirakawa received consulting fees from Taiho Pharmaceutical Co., Ltd. H. Ishigami received research funding from Taiho Pharmaceutical Co., Ltd., and drugs from Nippon Kayaku Co., Ltd.
: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. Informed consent to be included in the study, or the equivalent, was obtained from all patients.